Model to Market, Part 2: What Made It Live and What I Rejected
The tests, failed candidates and promotion decisions that determined which strategies could influence the competition account.
2 Aug 202613 min read
#validation
2 published articles.
What a Generative Drug-Discovery Pipeline Can—and Cannot—Prove
A technical retrospective on target-conditioned molecule generation, property screening and predicted affinity: what each metric means, where the original FGFR2 project overreached, and how I would validate it now.
2 Aug 202612 min read